Repligen Co. (NASDAQ:RGEN) Shares Acquired by Icon Wealth Advisors LLC

Icon Wealth Advisors LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2,081.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,571 shares of the biotechnology company's stock after acquiring an additional 31,078 shares during the quarter. Icon Wealth Advisors LLC owned approximately 0.06% of Repligen worth $4,847,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Andra AP fonden acquired a new position in shares of Repligen during the 2nd quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in Repligen during the second quarter worth approximately $33,000. UMB Bank n.a. increased its position in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

NASDAQ:RGEN opened at $141.39 on Friday. The firm has a 50-day moving average of $140.20 and a two-hundred day moving average of $143.62. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 5.56. The stock has a market cap of $7.92 billion, a P/E ratio of -382.12, a PEG ratio of 3.87 and a beta of 0.96. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the business posted $0.23 earnings per share. Repligen's revenue for the quarter was up 9.7% on a year-over-year basis. On average, research analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on RGEN shares. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a "peer perform" rating for the company. Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective on the stock. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Wednesday, November 13th. Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Finally, UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.